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nonbloody diarrhea. Microscopic colitis is more common 
in women than men and usually affects patients in 
their sixth and seventh decade. This article reviews 
the etiology and medical management of microscopic 
colitis. The etiology of microscopic colitis is unknown, 
but it is associated with autoimmune disorders, such 
as celiac disease, polyarthritis, and thyroid disorders. 
Smoking has been identified as a risk factor of mi­
croscopic colitis. Exposure to medications, such as 
non­steroidal anti­inflammatory drugs, proton pump 
inhibitors, and selective serotonin reuptake inhibitors, is 
suspected to play a role in microscopic colitis, although 
their direct causal relationship has not been proven. 
Multiple medications, including corticosteroids, anti­
diarrheals, cholestyramine, bismuth, 5­aminosalicylates, 
and immunomodulators, have been used to treat 
microscopic colitis with variable response rates. 
Budesonide is effective in inducing and maintaining 
clinical remission but relapse rate is as high as 
82% when budesonide is discontinued. There is 
limited data on management of steroid­dependent 
microscopic colitis or refractory microscopic colitis. 
Immunomodulators seem to have low response rate 
0%­56% for patients with refractory microscopic colitis. 
Response rate 66%­100% was observed for use of 
anti­tumor necrosis factor (TNF) therapy for refractory 
microscopic colitis. Anti­TNF and diverting ileostomy 
may be an option in severe or refractory microscopic 
colitis. 
Key words: Chronic diarrhea; Etiology of microscopic 
colitis; Collagenous colitis; Refractory microscopic 
colitis; Microscopic colitis; Lymphocytic colitis; Steroid­
dependent microscopic colitis
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Core tip: The etiology of microscopic colitis (MC) 
is unknown. There is a strong association with 
autoimmune disorders, smoking, and medications, 
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Abstract
Microscopic colitis is a common cause of chronic, 
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disease. While no specific genetic mutations have been 
identified as direct cause of MC, some studies have 
found common genetic abnormalities. For instance, 
there is an increased prevalence of human leukocyte 
antigen (HLA) DR3 DQ2 allele in patients with MC, 
and metalloproteinase 9 gene variations have been 
associated with CC[3]. 
Smoking is a risk factor for MC. In a prospective, 
Park T et al . Etiology and management of microscopic colitis
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Figure 1 Colonic biopsy. A: Lymphocytic colitis, hematoxylin and eosin stain. 
The key histological feature is increased number of intraepithelial lymphocytes 
with little or no crypt architectural distortion. The presence of > 20 intraepithelial 
lymphocytes per 100 surface epithelial cells is diagnostic of lymphocytic colitis 
(LC)[2]. Fewer than 5 intraepithelial lymphocytes per 100 surface epithelial 
cells are considered normal[2]. Inflammatory infiltration usually consists of 
lymphocytes and plasma cells but eosinophils and neutrophils may also be 
present; B: Collagenous colitis, hematoxylin and eosin stain. The black arrow 
points to the thickened subepithelial collagen band. Band thickness is 10-20 
μm in collagenous colitis (CC)[2]. Collagen band thickness < 3 μm is considered 
normal[2]; C: Collagenous colitis, trichrome stain. Collagen stains blue on 
trichrome stain. Trichrome stain can be useful when it is difficult to determine 
the thickness of collagen band on hematoxylin and eosin stain. This picture 
demonstrates a thickened subepithelial collagen band. 
such as non­steroidal anti­inflammatory drugs, proton 
pump inhibitors, and selective serotonin reuptake 
inhibitors. There are no societal guidelines on how to 
manage patients with MC. Data is strongest for the 
use of budesonide. Budesonide can rapidly induce 
clinical remission but relapse occurs frequently after 
discontinuation of budesonide. Anti­diarrheals may 
be used alone in mild MC or in conjunction with other 
therapies in moderate to severe MC. There is limited 
data on management of steroid­dependent or refractory 
MC but anti­TNF and diverting ileostomy may be options. 
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INTRODUCTION
Microscopic colitis (MC) is a common cause of chronic, 
nonbloody diarrhea. Up to 10%-20% of chronic 
diarrhea is thought to be secondary to MC. The 
incidence of MC in Sweden, Spain, and Iceland from 
the 1990s ranged from 1.1 to 5.2 per 100000 person-
years[1]. In a population based cohort study conducted 
from 1985 to 2001 in Olmsted County, Minnesota, 
the incidence of CC was 3.1 per 100000 and that 
of LC was 5.5 per 100000[1]. Poisson regression 
analysis showed that the incidence of MC increased 
over time, and the incidence of MC by the end of 
2001 was 19.6 per 100000[1]. MC typically affects 
patients in their 50-60 s and occurs more frequently 
in women than men. The diagnosis is made by both 
clinical history and endoscopic biopsies. While chronic 
watery diarrhea is the most common symptom, some 
patients with MC may also experience abdominal pain, 
fecal incontinence, and/or weight loss. Colonoscopy 
generally reveals normal colonic mucosa but colonic 
biopsy shows classic histological features: > 20 
intraepithelial lymphocytes per 100 epithelial cells in 
lymphocytic colitis (LC) and 10-20 μm of a thickened 
subepithelial collagen band in collagenous colitis (CC) 
(Figure 1). Inflammation in the lamina propria, with 
mainly mononuclear cells, may be seen in CC. Other 
etiologies, such as celiac disease, inflammatory bowel 
disease, and infectious colitis should be ruled out. 
ETIOLOGY
The etiology of MC is unknown. There is a strong 
association with autoimmune disorders, such as 
celiac disease, polyarthritis, and thyroid disorders 
(Table 1). Up to twenty to 60% of patients with LC 
and 17%-40% of patients with CC have autoimmune 
disease[2]. In fact, histological features of MC in the 
colon are present in 30% of patients with celiac 
case-control study conducted from 2007 to 2010 in 
Spain involving 255 patients, smoking was significantly 
associated with LC and CC (OR = 3.8 in LC, OR = 
2.4 in CC)[4]. Swedish study conducted by Vigren et 
al[5] also showed that smoking is associated with CC. 
Thirty-seven percent of patients with CC were smokers 
as compared to only 17% of patients in the control 
group (OR = 2.95). Subgroup analysis showed that 
the association of smoking with CC was most notable 
in the age group 16-44; 75% of patients in this age 
group were smokers as compared to 15% in the 
control group (odd ratio: 16.54). Smokers develop MC 
earlier than nonsmokers by a median of 14 years[6]. 
Medications are often implicated as a cause of MC. 
Non-steroidal anti-inflammatory drugs (OR = 4.6 in 
LC, OR = 3.8 in CC), proton pump inhibitors (OR = 2.7 
in LC, OR = 6.4 in CC), selective serotonin reuptake 
inhibitors (OR = 17.5 in LC), and beta-blockers (OR = 
3.6 in CC) are strongly associated with MC (Table 1)[4]. 
A population-based case-control study using a Dutch 
primary care database assessed the risk of MC from 
exposure to medications compared with community 
control as well as with colonoscopy control where 
subjects had negative colonoscopy and negative 
histology for MC[7]. This study showed that current use 
of proton pump inhibitor (OR = 10.6) and nonsteroidal 
anti-inflammatory drugs (OR = 5.6) significantly 
increased the risk of MC[7]. Diclofenac was the most 
commonly used non-steroidal anti-inflammatory 
drug, and omeprazole was the most commonly 
used proton pump inhibitor in this study. Selective 
serotonin reuptake inhibitors, beta-blockers, and ACE 
inhibitors increased the risk of MC when compared 
with community controls, but not when compared with 
colonoscopy controls[7]. 
A more recent theory centers around bacterial 
translocation in the gastrointestinal tract. Bacterial 
antigens or toxins are suspected to increase infla-
mmatory mediators in the colonic mucosa, leading to 
increased mucosal permeability, increased cytokines, 
degradation of the collagen matrix, and dysregulation 
of intestinal subepithelial myofibroblasts. No spe-
cific organisms have been identified in causing or 
exacerbating MC. Analysis of colonic biopsies of 
patients with MC demonstrated an increased amount 
of interferon-gamma, tumor necrosis factor alpha, 
and interleukin-1β in patients with MC as compared 
to patients without MC who underwent routine 
screening/surveillance colonoscopy, suggesting role 
of Th1 immune response in MC[8]. There was a trend 
towards increased level of interleukin-13 in patients 
with MC but interleukin-13 levels were not significantly 
different between MC and non-MC patients[8]. There 
was no difference in interleukin-8 level between the two 
groups[8]. Mucosal mRNA levels of interferon-gamma 
and interleukin-15 were 100 times greater and tumor 
necrosis factor alpha was 60 times greater in patients 
with MC as compared to patients with irritable bowel 
syndrome with diarrhea predominance, also supporting 
the role of Th1 immune response, which may be 
triggered by an unknown luminal antigen and ultimately 
leads to MC in susceptible individuals[9]. 
MANAGEMENT
There are no society guidelines on how to best manage 
patients with MC. While some provider will start with 
the most benign recommendations including lifestyle 
changes and work their way up to anti-diarrheals 
and steroids, others will go right to the most effective 
medications.
Lifestyle changes
As an initial approach, a thorough history should be 
taken in order to corroborate a temporal relationship 
between starting a new medication and the onset of 
symptoms. If suspected, offending medications should 
be discontinued if possible. Smoking cessation should 
also be encouraged. 
Anti-diarrheal medications (loperamide, diphenoxylate/
atropine) 
There are no randomized controlled trials comparing 
efficacy of antidiarrheals against placebo or other 
medical therapy for MC. A retrospective registry review 
of 163 patients with CC showed a 71% efficacy rate 
(49 out of 69 patients) of loperamide[10]. Consensus is 
that anti-diarrheals may be used alone in mild MC or in 
conjunction with other therapies in moderate to severe 
MC to reduce frequency of diarrhea. 
Bismuth
In an animal study, bismuth subsalicylate and bis-
muth subcitrate enemas significantly reduced the 
macroscopic and microscopic appearance of the 2, 4, 
6-trinitrobenzene sulfonic acid (TNBS)-induced colitis 
in rats compared to TNBS-induced rats treated with 
saline enemas[11]. TNBS-induced colitis is a model 
for chronic inflammation and ulceration seen in 
inflammatory bowel disease rather than MC; therefore, 
this animal study does not directly demonstrate benefit 
of bismuth in MC. However, its effect on reduction 
of microscopic injury scores can be used to infer its 
benefit in MC. A prospective study of 12 patients with 
MC treated with bismuth subsalicylate 262 mg/d for 
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Table 1  Factors associated with microscopic colitis
Autoimmune disorder (type 1 diabetes, rheumatoid arthritis, celiac 
disease, thyroid disorders)
Nonsteroidal anti-inflammatory drugs 
Proton pump inhibitors 
Serotoin reuptake inhibitors 
Statins
Beta-blockers 
Smoking
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Similar randomized controlled trials comparing 
induction of budesonide followed by maintenance 
with budesonide vs placebo have shown high clinical 
remission rate 77%-96% in budesonide group (Table 
2). A Cochrane review by Chande et al[17] showed that 
the pooled odds ratio: for inducing clinical response 
with budesonide was 12.32 (95%CI: 5.53-27.46) and 
for maintaining clinical response was 8.82 (95%CI: 
3.19-24.37)[17]. The number needed to treat was 2 
for each outcome. Additionally, patients treated with 
budesonide had a higher rate of complete response 
than those treated with prednisone (82.5% vs 52.9%; 
OR = 4.18; 95%CI: 1.3-13.5) and were less likely to 
recur than those treated with prednisone (HR = 0.38; 
95%CI: 0.18-0.85; P = 0.02)[18].
A multicentered, randomized controlled trial of 92 
patients comparing budesonide, mesalamine, and 
placebo for MC showed that budesonide was more 
effective than mesalamine (80% vs 44%, P = 0.0035) 
and placebo (80% vs 59.5%, P = 0.072) in inducing 
clinical remission at 8 wk[15]. Histological remission rate 
was the highest in patients treated with budesonide 
(87%) as compared to mesalamine (45%) and 
placebo (50%)[15]. The rates of adverse events were 
similar among budesonide, mesalamine, and placebo 
groups (47%, 68%, 54%)[15]. The most frequent 
adverse events were nasopharyngitis, headaches, and 
dyspepsia. 
Although budesonide has been shown to rapidly 
induce clinical response, relapse occurs frequently 
after discontinuation of budesonide. Relapse rate 
is estimated to be as high as 26%-82% (Table 2). 
Median time to relapse after stopping active treatment 
was 39 d[19]. Patients with baseline diarrhea frequency 
> 5 per day (HR = 1.67), duration of diarrhea > 12 mo 
(HR = 1.82), and absence of budesonide maintenance 
therapy (HR = 2.73) were found to be at highest risk 
for relapse[20]. Other factors associated with relapse 
were advanced age (P = 0.047), a higher number 
of bowel movements per day at randomization after 
induction period (P = 0.009), and a higher number of 
bowel movements per day at baseline (P = 0.041)[16]. 
Immunomodulators 
Immunomodulators, such as azathioprine, 6-mercap-
topurine, and methotrexate, have been tried in 
patients with refractory MC or steroid dependent MC 
(Table 3). There are no randomized controlled trials 
studying efficacy of these medications for MC, and 
data on use of these medications for refractory MC is 
limited. 
In a small study of 9 patients with CC who were 
intolerant or nonresponsive to budesonide, the 
patients were treated with methotrexate 15-25 
mg/wk subcutaneously for 12 wk. Four of 9 patients 
discontinued methotrexate due to adverse effects 
(nausea, allergic reaction, worsening diarrhea), and 
none of the patients achieved clinical remission at 
8 wk showed a 92% rate of clinical remission and a 
75% rate of histological resolution of MC[12]. Mean time 
to response was 2 wk. At 7-28 mo follow-up, 75% of 
patients remained in remission. 
Cholestyramine
There are no randomized controlled trials demon-
strating efficacy of cholestyramine for MC. In a small 
retrospective study involving 27 patients with CC, 12 
out of 27 (44%) patients were found to have abnormal 
bile acid absorption. Eleven out of these 12 patients 
(92%) reported improvement in diarrhea within one 
week when treated with bile acid binding agents 
(cholestyramine 4 g 2-3 times per day, or colestipol 5 
g 2-3 times per day if the patients could not tolerate 
the smell or taste of cholestyramine)[13]. Ten out of 15 
(67%) patients with CC and normal bile acid absorption 
reported improvement in diarrhea when treated with 
bile acid binding agents[13]. Overall, 78% of patients 
with CC experienced improvement in diarrhea with bile 
acid binding agents. In a retrospective registry review 
of patients with CC, cholestyramine was effective in 26 
out of 44 patients (59%)[10]. 
Aminosalicylates (5-aminosalicylic acid)
In a study of 64 patients with MC treated with 
mesalamine 2.4 g/d vs mesalamine 2.4 g/d plus 
cholestyramine 4 g/d for 6 mo, the rates of remission 
were similar between the two groups. Eighty four 
percent of patients experienced clinical remission 
within the first 2 wk of treatment[14]. Clinical remission 
occurred earlier in patients treated with mesalamine 
plus cholestyramine than those treated with mesalamine 
alone. 
Other studies have demonstrated little benefit of 
aminosalicylates. In a double-blinded, randomized 
placebo-controlled trial of 92 patients comparing efficacy 
of budesonide, mesalamine, and placebo, interim 
analysis found mesalamine to be less effective than 
placebo in inducing clinical remission and the review 
board recommended closure of this study arm[15]. The 
rate of clinical remission was 44% in mesalamine group 
and 59.5% in placebo group at 8 wk[15]. 
Corticosteroids
A number of medications have been studied to induce 
clinical remission, and the evidence is strongest for 
the use of budesonide. A prospective, double-blinded, 
randomized controlled trial comparing induction 
of budesonide (9 mg/d for 4 wk, 6 mg/d for 2 wk, 
alternating doses of 6 and 3 mg/d for 2 wk) followed 
by maintenance dose of budesonide (alternating 
6 and 3 mg/d) vs placebo for 1 year showed that 
maintenance of clinical remission rate was higher in 
budesonide group (61.4%) than in the placebo group 
(16.7%)[16]. Clinical remission rate after induction 
period was 84.5% and the median time to remission 
was 10.5 d[16]. 
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week 12[21]. 
A multicentered European study showed 41% 
overall response rate to thiopurines (azathioprine 
or 6-mercaptopurine) in patients who were steroid 
dependent or failed other medical therapy, such as 
loperamide, cholestyramine, budesonide, mesalamine, 
and methotrexate[22]. Nine patients with steroid 
intolerance, refractoriness, or dependence were treated 
with azathioprine 2 mg/kg per day and were followed 
for 26 mo. Eight out of 9 patients (89%) had complete 
(56%) or partial (33%) response to azathioprine and 
were able to discontinue corticosteroids. One out of 
9 patients (11%) had persistent severe diarrhea and 
required an ileostomy.
Anti-tumor necrosis factor
There are no randomized controlled trials studying 
efficacy of anti-tumor necrosis factor (TNF) for 
refractory MC, but there are multiple case reports of 
clinical response after induction therapy with either 
infliximab or adalimumab (Table 3). Aram et al[23] 
reported a patient with lymphocytic enterocolitis who 
failed corticosteroids, antibiotics, cholestyramine, 
azathioprine, and tincture of opium. This patient was 
treated with infliximab 5 mg/kg at 0, 2 and 6 wk with 
resolution of diarrhea. There was a report of a patient 
with steroid-dependent MC who failed to respond 
to diphenoxylate/atropine, loperamide, bismuth, 
mesalamine, cholestyramine, octreotide, alosetron, 
tincture of opium, and Boswellia serrata extract was 
treated with infliximab 5 mg/kg and methotrexate 
12.5 mg per week. After 6 mo, the patient remained 
asymptomatic and free of corticosteroids[24].
Several small case series also demonstrated im-
provement. Long-term remission (more than 1 year) 
was achieved in 3 out of 4 patients with refractory 
MC who were treated with anti-TNF[25]. One patient 
developed Stevens Johnson syndrome after starting 
infliximab and relapsed when switched to adalimumab; 
therefore, anti-TNF was discontinued. The patient 
underwent colectomy. In another series, three patients 
with MC who failed loperamide, cholestyramine, 
budesonide, and methotrexate were treated with 
adalimumab. All 3 patients achieved clinical remission 
at week 6 but 1 patient stopped therapy due to 
adverse effects (vomiting, abdominal pain)[26]. 
Diverting ileostomy
There are case reports of patients successfully 
undergoing colectomy or diverting ileostomy for 
refractory and severe MC. The observational trend 
from these case reports is that both symptoms and 
histology improve after surgery but can recur when 
bowel continuation is restored. 
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Table 2  Summary of studies demonstrating efficacy of budesonide for treating microscopic colitis
Number of 
patients
Mean age (yr) Treatment Remission rate1 Relapse rate2
Miehlke et al[31], 2008 48 57.5 Budesonide 9 mg/d for 6 wk, followed by 
budesonide 6 mg/d vs placebo for 6 mo
Short-term 96% 26% vs 65% placebo, 
P = 0.022Long-term 74% vs 35% placebo, 
P = 0.008
Bonderup et al[19], 2009 34 62.8 Budesonide 9 mg/d for 6 wk, followed by 
budesonide 6 mg/d vs placebo for 24 wk
Long-term 53%
76.5% vs 12% placebo, P < 0.001
Miehlke et al[15], 2014 92 58.8 Budesonide 9 mg/d vs placebo for 8 wk At 8 wk, 35%
80% vs 59.5% placebo, P = 0.072
Münch et al[16], 2014 92 56.7 Budesonide 9 mg/d for 8 wk, followed by 
budesonide 4.5 mg/d vs placebo for 6 mo
Short-term 84.5% 82.1% vs 12.5% 
placeboLong-term
61.4% vs 16.7% placebo, P < 0.001
1Short-term remission rate is within 6 wk during induction phase. Long-term remission rate is at 6 mo of maintenance therapy, unless otherwise specified; 
2After discontinuation of therapy.
Table 3  Response rate to immunomodulators and anti-tumor necrosis factor for severe or refractory microscopic colitis
Number of 
patients
Mean age (yr) Treatment Duration of 
therapy
Response rate
Münch et al[22], 2013 46 59 Azathioprine or 6-MP 2 mg/kg per day Variable, 1-57 mo   41%
Pardi et al[30], 2001   9 62 Azathioprine or 6-MP 2 mg/kg per day 26 mo   56%
Münch et al[21], 2013   9 62 Methotrexate 15-25 mg/wk 12 wk     0%
Esteve et al[25], 2011   4 59 Infliximab 5 mg/kg at 0, 2, 6 wk then every 6-8 wk 
intravenously
Variable, 5-14 mo   75%
Münch et al[26], 2012   3 55 Adalimumab induction1 then 40 mg subcutaneously every 
2 wk
6 wk   66%
Pola et al[24], 2013   1 58 Infliximab 5 mg/kg at 0, 2, 6 wk then every 8 wk 
intravenously
6 mo 100%
1Adalimumab induction: 160 mg (week 0), 80 mg (week 2), and 40 mg (week 4).
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In one case report, a 33 year-old patient with 5 
years of chronic diarrhea from CC not responsive to 
Asacol and prednisone underwent total protocolectomy 
followed by ileal pouch anal anastomosis. At 2 year 
follow-up, she was having multiple bowel movements 
per day but diarrhea resolved and she was able to 
return to full-time job[27]. 
In another, a 59 year-old patient with CC who 
previously failed loperamide, prednisolone, budesonide, 
5-aminosalicylic acid, cholestyramine, and norfloxacin 
underwent loop ileostomy[28]. Two to 4 mo after 
loop ileostomy, colonic biopsies showed resolution 
of subepithelial damage, but her clinical course was 
complicated by Clostridium difficile infection and 
problems with the stoma. One year later, the patient 
improved clinically and loop ileostomy was closed. 
The patient started budesonide 6mg daily after bowel 
restoration but relapsed with symptoms of CC. 
In a series of patients, nine patients with MC re-
fractory to medical therapy (sulfasalazine, mepacrine, 
corticosteroids, mesalamine, cholestyramine, 
loperamide, metronidazole) underwent ileostomy in 
between 1981-1992[29]. All patients experienced clinical 
and histological remission. The ileostomy was taken 
down in 5 patients after a diversion period of 4-15 mo. 
Diarrhea recurred in 4 out of 5 of these patients and 3 
of them underwent additional surgery.
CONCLUSION
MC is characterized by chronic, watery diarrhea and 
subepithelial changes. Conservative therapy, such 
as discontinuation of offending mediations and trial 
of loperamide and/or bismuth, may be successful in 
treating non-severe MC. Budesonide can rapidly induce 
clinical remission and can maintain remission, but 
relapse occurs frequently after withdrawal of therapy. 
Methotrexate and mesalamine do not appear to be 
effective as monotherapy for MC. There is limited data 
to support the use of immunomodulators in refractory 
or steroid-dependent MC. Anti-TNF or ileostomy may 
be an option for severe, refractory MC; however, 
their efficacy has not been proven in randomized 
controlled trials yet, and their risk and benefits need 
to be discussed in detail with the patient prior to 
recommending these therapy. 
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